JEFFREY B KINDLER
CIK 1174454 · Executive Chairman · last filed 2026-06-12
JEFFREY B KINDLER is an Executive Chairman who has filed 178 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing, for PRAX, was dated Jun 12, 2026. Across all open-market trades the lifetime net is −$1.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $23.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$23.85M
10
178
-$1.08M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRAX | Director | 2,537 | $296.19 | $751.4K | $0 | 2 | 2026-06-12 |
| Terns Pharmaceuticals, Inc. (TERN) Delisted | Director | — | $52.95 | — | $0 | 9 | 2026-05-05 |
| PGEN | Director | 202,100 | $5.51 | $1.11M | -$1.71M | 17 | 2026-03-16 |
| PRGO | Director | 10,559 | $10.28 | $108.5K | -$497.5K | 15 | 2025-05-16 |
| PPD, Inc. (PPD) Delisted | Director | 0 | $47.28 | $0 | $499.5K | 4 | 2021-12-08 |
| VTVT | Executive Chairman | 875 | $31.23 | $27.3K | $0 | 7 | 2020-06-15 |
| SIGA | Director | 127,339 | $3.27 | $417.0K | $0 | 10 | 2020-05-22 |
| PRECIGEN, INC. (XON) Delisted | Director | 84,040 | — | — | $627.7K | 16 | 2019-03-26 |
| CMG | Director | 15,650 | $33.62 | $526.1K | $0 | 2 | 2013-05-17 |
| PFE | Former Chairman & CEO | 827,296 | $25.27 | $20.91M | $0 | 91 | 2010-12-17 |
Recent Filings
178 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-12 | PRAX | Grant (A) | +1,371 | $0 | EDGAR |
| 2026-05-28 | PRGO | Notice (144) | −14,357 | -$164.2K | EDGAR |
| 2026-05-05 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Disp (D) | — | $0 | EDGAR |
| 2026-03-16 | PGEN | Exer (M) | +71,839 | $0 | EDGAR |
| 2026-03-12 | PGEN | Grant (A) | +19,658 | $69.0K | EDGAR |
| 2026-02-10 | PRAX | Grant (A) | +1,166 | $0 | EDGAR |
| 2026-02-02 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-12-16 | PGEN | Sell (S) | −235,467 | -$855.9K | EDGAR |
| 2025-12-12 | PGEN | Notice (144) | −235,467 | -$868.9K | EDGAR |
| 2025-10-01 | PGEN | Sell (S) | −174,360 | -$604.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.